[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357125-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357125-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lipid-nanoparticles-and-extracellular-vesicles-emerging-cell-free-therapeutic-platforms-for-hepatobiliary-cancers","Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers","","Hepatobiliary cancers drive cancer-related mortality due to late diagnosis, poor prognosis, and frequent failure of current treatments in advanced disease. This review examines lipid nanoparticles (LNPs) as delivery systems that can transport natural biomolecules or engineered drugs, and summarizes how extracellular vesicles (EVs) shape the tumor microenvironment and contribute to progression, chemoresistance, and immune evasion. It evaluates cell-free therapeutic LNP-and EV-based platforms for delivering RNA, small molecules, and proteins to improve diagnosis and treatment outcomes, focusing on hepatocellular carcinoma and cholangiocarcinoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lipid-nanoparticles-and-extracellular-vesicles-emerging-cell-free-therapeutic-platforms-for-hepatobiliary-cancers/357125/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lipid-nanoparticles-and-extracellular-vesicles-emerging-cell-free-therapeutic-platforms-for-hepatobiliary-cancers/357125.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are new therapeutic strategies needed for hepatobiliary cancers?","Question",{"text":63,"@type":64},"Current standard treatments are often limited by late-stage diagnosis, poor prognosis, and reduced effectiveness in advanced disease, including drug resistance and complex tumor microenvironments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles do lipid nanoparticles (LNPs) play in this review?",{"text":68,"@type":64},"LNPs are discussed as promising delivery vehicles that transport natural biomolecules or engineered drugs for targeted tumor therapy and related applications such as vaccines.",{"name":70,"@type":61,"acceptedAnswer":71},"How are extracellular vesicles (EVs) relevant to hepatobiliary cancers?",{"text":72,"@type":64},"EVs are highlighted for their ability to modulate the tumor microenvironment, promote progression, contribute to chemoresistance, and enable escape from immune recognition, with potential as biomarkers and therapeutic agents.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357125,1790576066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OPEN ACCESS  \nEDITED BY  \nWenbo Zhang,  \nThe University of Chicago, United States  \nREVIEWED BY  \nShivaani Krishna,  \nBay Area Institute of Science, United States  \nMasoud Lahouty,  \nTabriz University of Medical Sciences, Iran  \n*CORRESPONDENCE  \nGabriele Saccu,  \n [gabriele.saccu@childrens.harvard.edu](gabriele.saccu@childrens.harvard.edu)[ ](gabriele.saccu@childrens.harvard.edu)Sharmila Fagoonee,  \n sharmila.fagoonee@unito. it RECEIVED 16 February 2026 REVISED 04 May 2026 ACCEPTED 11 May 2026 PUBLISHED 28 May 2026  \nCITATION  \nSaccu G and Fagoonee S (2026) Lipid nanoparticles and extracellular vesicles:  \nemerging cell free therapeutic platforms for hepatobiliary cancers.  \nFront. Cell Dev. Biol. 14:1812373 .  \ndoi: 10.3389/fcell.2026.1812373  \nCOPYRIGHT  \n© 2026 Saccu and Fagoonee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTYPE Review  \nPUBLISHED 28 May 2026  \nDOI 10.3389/fcell.2026.1812373  \nLipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers  \nGabriele Saccu 1* and Sharmila Fagoonee 2*  \n1Boston Children’s Hospital, Pathology Department, Harvard University, Boston, MA, United States, 2Institute of Biostructure and Bioimaging (CNR) and Molecular Biotechnology Center “Guido Tarone”, Turin, Italy  \nHepatobiliary cancers are major contributors to cancer-related mortality, mainly due to late-stage diagnosis, poor prognosis, and limited effectiveness of current treatments in advanced disease. Standard therapies comprise surgical resection, liver transplantation, and systemic agents including tyrosine kinase inhibitors and immune checkpoint inhibitors, but their efficacy is often hindered by the development of drug resistance, underlying the urgent need for novel therapeutic strategies. Lipid nanoparticles (LNPs) have emerged as promising delivery vehicles due to their favorable physicochemical properties, enabling the transport of natural biomolecules or engineered drugs for targeted tumor therapy. LNPs are also being explored as platforms for cancer therapy and vaccines. Moreover, recent advances underscore the key role of extracellular vesicles (EVs) in modulating the tumor microenvironment, promoting tumor progression, chemoresistance, and escape from immune recognition and destruction (immune evasion) in hepatobiliary cancers. EVs are being investigated both as biomarkers for early detection and as therapeutic agents, with engineered or drug-loaded EVs showing potential for targeted drug delivery and tissue repair in liver diseases, including cancer. This review highlights the potential of cell-free therapeutic LNP-and EV-based platforms, standalone or in combination, for RNA, small molecules and proteins delivery in improving diagnosis and treatment outcomes in hepatobiliary cancers, in particular, hepatocellular carcinoma and cholangiocarcinoma.  \nKEYWORDS  \nbiomarkers, cancer therapy, drug delivery, extracellular vesicles, hepatobiliary cancers, lipid nanoparticles, mRNA vaccine  \n1 Introduction  \nHuman hepatobiliary cancers encompass aggressive malignancies that originate in the liver, bile ducts and gallbladder, comprising hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), gallbladder carcinoma (GBC) . HCC originates in the liver cells while CCA, which arises from the bile ducts, is further classified as intrahepatic or extrahepatic (Spencer et al., 2023) . Collectively, CCAs and gallbladder cancer are often referred to as biliary tract cancers (BTCs) . The lack of specific symptoms in early stages of hepatobiliary tumors leads to diagnosis mostly ","cbCaifM8VI3GR1Q6","https://ap.wps.com/l/cbCaifM8VI3GR1Q6","pdf",3041865,21,"English","# Introduction\n## Hepatobiliary cancer background and challenges\n# LNP and EV therapeutic platforms (overview)\n## Delivery of RNA, small molecules and proteins","[{\"question\":\"Why are new therapeutic strategies needed for hepatobiliary cancers?\",\"answer\":\"Current standard treatments are often limited by late-stage diagnosis, poor prognosis, and reduced effectiveness in advanced disease, including drug resistance and complex tumor microenvironments.\"},{\"question\":\"What roles do lipid nanoparticles (LNPs) play in this review?\",\"answer\":\"LNPs are discussed as promising delivery vehicles that transport natural biomolecules or engineered drugs for targeted tumor therapy and related applications such as vaccines.\"},{\"question\":\"How are extracellular vesicles (EVs) relevant to hepatobiliary cancers?\",\"answer\":\"EVs are highlighted for their ability to modulate the tumor microenvironment, promote progression, contribute to chemoresistance, and enable escape from immune recognition, with potential as biomarkers and therapeutic agents.\"}]","Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers | PDF",1790129086,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f866d7866294c2c1c3a03581b3a2e1c.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19141b6e6f67d4181da6f0f9251807f3.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93682fffbde5a402b753940c7e8295c5.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/193009446e54a68de376c7d43a2e4187.webp",980,1385]